Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma.

Science translational medicine·2026
Same author

C-C chemokine receptor 4 is a candidate for regulatory T-cell-depletion immunotherapy in differentiated thyroid cancer.

Auris, nasus, larynx·2025
Same author

Germline or somatic mutations in genes encoding microRNAs as biomarkers predicting the risk of adult T-cell leukemia/lymphoma.

Journal of human genetics·2025
Same author

Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors.

Journal for immunotherapy of cancer·2025
Same author

Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.

International journal of hematology·2024
Same author

Regulatory T-cells activated in metastatic draining lymph nodes possibly suppress cancer immunity in cancer tissues of head and neck squamous cell cancer.

Pathology international·2024
Same journal

Characterization of distant metastases in salivary gland cancer patients undergoing upfront surgery followed by postoperative radiation therapy: a multicenter analysis.

Japanese journal of clinical oncology·2026
Same journal

A Lynch syndrome patient with multiple cancers who was found to have a novel pathogenic variant generating aberrant splicing of MLH1.

Japanese journal of clinical oncology·2026
Same journal

Age-standardized mortality-to-incidence ratio for lymphoma in the world.

Japanese journal of clinical oncology·2026
Same journal

Real-world trends in anti-androgen prescribing and associated costs for prostate cancer in Japan: a nationwide analysis.

Japanese journal of clinical oncology·2026
Same journal

Progress in siRNA nucleic acid therapeutics and challenges in their application to cancer treatment.

Japanese journal of clinical oncology·2026
Same journal

Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer.

Japanese journal of clinical oncology·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Current status of immunotherapy.

Susumu Suzuki1, Takashi Ishida2, Kazuhiro Yoshikawa3

  • 1Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute suzukis@aichi-med-u.ac.jp.

Japanese Journal of Clinical Oncology
|January 29, 2016
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors like ipilimumab, nivolumab, and pembrolizumab represent a breakthrough in cancer immunotherapy. Targeting the tumor

Keywords:
clinical trialsimmunologyimmunotherapy

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Related Experiment Videos

Last Updated: Mar 26, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
  • Anti-CTLA-4 (ipilimumab) and Anti-PD-1 (nivolumab, pembrolizumab) antibodies show efficacy in various cancers.
  • ICIs enhance anti-cancer immunity by modulating the tumor microenvironment.

Purpose of the Study:

  • To review the impact of ICIs in cancer immunotherapy.
  • To highlight the importance of understanding the immune suppressive tumor microenvironment.
  • To explore novel therapeutic strategies targeting immune suppression.

Main Methods:

  • Review of clinical trial data for ipilimumab, nivolumab, and pembrolizumab.
  • Analysis of research on immune suppression mechanisms in cancer.
  • Identification of key molecules and cells involved in the tumor immune microenvironment.

Main Results:

  • ICIs demonstrate durable responses in advanced melanoma and other solid tumors.
  • Controlling the immune suppressive tumor microenvironment is crucial for effective cancer immunotherapy.
  • Research focus has shifted towards understanding and targeting immune suppression.

Conclusions:

  • ICIs are a significant advancement in cancer immunotherapy.
  • Further research into the immune suppressive tumor microenvironment is essential.
  • Novel immunotherapies may emerge from targeting these suppressive pathways.